Advisory Committees
Science Advisory Committee
William Foulkes (Chair)
McGill Centre for Translational Research in Cancer, Canada
Rachel Butler
North Thames GLH, Great Ormond Street Hospital
Majorlijn Ligtenberg
Radboud University Medical Center, Netherlands
Mary Porteous
University of Edinburgh
Our Science Advisory Committee consists of four independent members drawn from leading scientists broadly representing the programme diversity.
​
The committee meet annually, along with CRUK and PPI representation, to monitor progress and provide scientific evaluation of the CGCV program of research to the programme and work-package leads. The feedback received from the SAC is used to direct future research and program strategy.
CanVIG Steering and Advisory Committee (CStAG)
Alison Calloway (Co-Chair)
Salisbury NHS Foundation Trust
Miranda Durkie (Co-Chair)
Sheffield University Hospitals NHS Foundation Trust
Rachel Robinson
Leeds Teaching Hospitals NHS Trust
George Burghel
Manchester University NHS Foundation Trust
James Drummond
Cambridge University Hospitals NHS Trust
Ian Berry
Leeds Teaching Hospitals NHS Trust
Andrew Wallace
Manchester University NHS Foundation Trust
CStAG is formed of NHS Clinical Laboratory Scientist representatives from across the UK.
​
The committee has been established from members of CanVIG, a group formed to improve the consistency of cancer genetic variant interpretation in the UK. The members are focussing the working priorities of CanVIG-UK and are an expert group of advisors supporting work-package 2.
Primary Care Panel
Imran Rafi
Senior Lecturer St George's University of London
RCGP Joint Clinical Champion Genomics
GP Surrey Downs
Judith Hayward
GPwSI in Genetics, Yorkshire and Humber Genomics Medicine Centre; Primary Care Adviser to Health Education England Genomics Education Programme; RCGP Joint Clinical Champion in Genomics Medicine; GP, Shipley Medical Practice, Affinity Care
As RCGP Joint Clinical Champions in Genomics facilitating the adoption and diffusion of new knowledge within primary care, our panel leads have a wealth of expertise to contribute across the CGCV programme.
​
The wider panel membership remains flexible to suit the needs of programme, with Imran and Judith acting as a point of liaison between CGCV researchers and the primary care community. In particular, the panel are involved with external review of clinical guidelines developed in work-package 3.
Oncology Panel
Ellen Copson (Chair)
University Hospital Southampton Foundation NHS Trust; Associate Professor in Medical Oncology, University of Southampton
​
Dr Copson is a practising medical oncologist interested in precision medicine and germline cancer susceptibility, as well as national lead for the oncogenetics training working party.
The oncology panel membership will be flexible to suit the different needs across the CGCV programme. In particular, our clinical education work-package (5) investigators will be collaborating with the oncogenetics training working party and oncologists will also be involved in external review of clinical guidelines developed in work-package 3.
Clinical Guideline Group
Anjana Kulkani (Chair)
Guy's and St Thomas' NHS Foundation Trust
Julian Adlard
Yorkshire and North East
Kei-Ren Ong
Wessex and West Midlands
Muna Ahmed
London North
Carole Brewer
South West
Alex Murray, Tabib Dahir
Devolved Nations
​
Other regions are represented by our work package investigators.
The Clinical Guideline Group supports work package 3 and is formed of Clinical Genetics specialists representing all regions of the UK.
​
The group is involved at every stage of guideline development, as they review the evidence collated by work-package staff and establish consensus recommendations (clinical guidelines) for genetic testing and management of patients at elevated genetic risk of cancer.
The work of the group is also sent for external review by gene-specific experts, our primary care and oncology panels, work-package 4 genetic counsellor, and patient representatives.